The Compa y’s atio ally-lice sed pha maceutical dist ibutio -focused subsidia y will cu e tly emai Wellgistics, LLC.
“Reb a di g ou pha macy a d pha macy hub focused e tities u de the Co exa Health umb ella is aimed at c eati g a disti ctio betwee ou pha macy-focused divisio a d the pe di g additio of the othe ope ati g healthca e se vices-focused divisio s i telemedici e a d diag ostic labo ato y se vices,” said Ge ald Commissio g, I te im Co-CEO of DataMEDS. “We a e also p epa i g fo the expa sio of ou a tificial i tellige ce platfo m Ei stei Rx that cu e tly sits withi ou pha macy hub as we i teg ate the comme cial healthca e delive y i tellectual p ope ty lice sed f om DataVault AI I c. (NASDAQ:DVLT) to the p e-existi g Pha macyChai ™ blockchai -e abled pha maceutical se ializatio t acki g lice se.”
“The p oposed acquisitio of pha maceutical-adjace t medical foods ma ufactu e a d “Health Lives He e” co sume healthca e app p ovide Tollo Health, LLC is expected to give us a u ique cost-alig ed custome acquisitio ma keti g oppo tu ity th ough the Health Lives He e i itiative bei g foste ed i pa t e ship with Natio al Football League Alum i Health (“NFLAH”),” co ti ued M . Commissio g. “Fu the , the p oposed acquisitio of the QOLPOM i tellectual p ope ty po tfolio elated to the biomet ic assessme t of d ug egime complia ce via pha macody amic espo se co fi matio th ough app-e abled wea ables a d the d o e home delive y of patie t p esc iptio s e abled via biomet ic co fi matio is expected to fu the diffe e tiate ou u ique di ect-to-co sume se vices offe i g bei g tailo ed fo healthca e i the u al commu ities that the Co exa Health i depe de t pha macy etwo k cu e tly se vices, while simulta eously p ovidi g pha maceutical ma ufactu e s with i c eased u al healthca e access a d the tailo ed de-ide tified health outcomes data they so desi e, especially i the GLP-1 ago ist space that is the i itial ta get of the NFLAH-pa t e ed i itiative.”
DataMeds AI, I c. (fo me ly Wellgistics Health) is a leadi g Health IT compa y that focuses o the ve tical i teg atio of tech ology, pha macy, pha maceutical-adjace t a d telemedici e busi ess u its to delive a bette healthca e expe ie ce fo co sume s. Headqua te ed i Tampa, Fla., DataMeds AI i co po ates the a tificial i tellige ce platfo m Ei stei Rx™ a d blockchai -e abled sma t co t acts platfo m Pha macyChai ™ i to the Health Lives He e mobile applicatio , a d its Co exa Health subsidia y p ovides pha macy a d pha macy se vices, i cludi g the dist ibutio of p oducts developed by Tollo Health, LLC.
This p ess elease co tai s fo wa d-looki g stateme ts withi the mea i g of the P ivate Secu ities Litigatio Refo m Act of 1995. Fo wa d-looki g stateme ts i clude, without limitatio , stateme ts ega di g: the Compa y’s o -bi di g lette of i te t to acqui e a co t olli g i te est i Tollo Health, LLC, a d the a ticipated timi g, st uctu e, te ms a d completio of that t a sactio ; the Compa y’s p oposed acquisitio of the QOLPOM i tellectual p ope ty po tfolio a d the a ticipated developme t a d i teg atio of that tech ology; the Compa y’s lice se of, a d pla s to i teg ate, healthca e delive y i tellectual p ope ty f om DataVault AI I c.; the Compa y’s pla s to expa d i to telemedici e a d diag ostic labo ato y se vices; the Compa y’s p oposed t a sactio with DataVault AI I c., Scilex Holdi g Compa y, EOS Holdi gs a d HealthB idge Adviso s; the satisfactio o waive of closi g co ditio s applicable to a y of the fo egoi g; the eceipt of stockholde app oval a d a y othe equi ed app ovals; the Compa y’s a ticipated busi ess st ategy, ope ati g pla s a d g owth oppo tu ities; the i teg atio of telemedici e, pha macy, labo ato y, wea able-device, a tificial i tellige ce, blockchai a d data-ma ageme t tech ologies; the p oposed developme t, comme cializatio a d expa sio of Ei stei Rx AI, Pha macyChai , Health Lives He e a d elated platfo ms; the a ticipated g owth of the ma ket fo Lo g COVID p oducts a d elated t eatme t app oaches; the Compa y’s ability to empowe patie ts to access, ma age, co t ol o mo etize health data; the a ticipated be efits of the Compa y’s tech ology platfo ms, st ategic elatio ships a d busi ess combi atio s; the Compa y’s capitalizatio , outsta di g secu ities, lock-up a a geme ts, public float a d egist atio stateme ts; the Compa y’s ability to mai tai complia ce with Nasdaq listi g sta da ds; a d the Compa y’s liquidity, capital esou ces a d ability to fu d ope atio s.
Fo wa d-looki g stateme ts a e based o cu e t expectatio s, estimates, p ojectio s a d assumptio s a d a e subject to isks a d u ce tai ties that could cause actual esults to diffe mate ially f om those exp essed o implied by such stateme ts. These isks a d u ce tai ties i clude, amo g othe s: the isk that the Compa y’s p oposed acquisitio of a co t olli g i te est i Tollo Health, LLC may ot be completed o the a ticipated te ms o timeli e, o at all, i cludi g because the pa ties have ot yet executed defi itive ag eeme ts; the isk that the p oposed t a sactio with DataVault AI I c., Scilex Holdi g Compa y, EOS Holdi gs a d HealthB idge Adviso s may ot be completed o the a ticipated te ms o timeli e, o at all; the isk that closi g co ditio s may ot be satisfied o waived; isks elated to i teg ati g multiple busi esses, tech ologies a d platfo ms; isks elated to the developme t, comme cializatio , adoptio , scalability a d egulato y t eatme t of a tificial i tellige ce, blockchai -e abled data ma ageme t, telemedici e, pha macy, labo ato y, wea able-device a d digital health tech ologies; isks elated to the egulato y classificatio a d ma keti g claims applicable to dieta y suppleme ts a d medical foods, i cludi g Tollovid a d Galactovid; the isk that the Compa y’s p oposed acquisitio of the QOLPOM i tellectual p ope ty po tfolio may ot be completed o the a ticipated te ms o timeli e, o at all; the isk that the Compa y’s lice se of i tellectual p ope ty f om DataVault AI I c. may be te mi ated, may ot be i teg ated as a ticipated, o may ot esult i the a ticipated be efits; isks elated to the Compa y’s ability to successfully develop, lau ch, scale o obtai ecessa y lice su e o egulato y app oval fo its pla ed telemedici e a d diag ostic labo ato y se vice li es; isks elated to healthca e p ivacy, cybe secu ity, data ow e ship, data mo etizatio a d complia ce with applicable healthca e, pha macy, co sume p otectio , data p otectio a d secu ities laws; isks elated to the Compa y’s liquidity, capital esou ces, i debted ess, dilutio , outsta di g secu ities, egist atio stateme ts a d ability to aise additio al capital; isks elated to mai tai i g complia ce with Nasdaq listi g sta da ds; ma ket, egulato y, competitive a d ope atio al isks affecti g the healthca e, pha macy, pha maceutical dist ibutio , a tificial i tellige ce, tech ology a d digital asset secto s; a d othe isks desc ibed i the Compa y’s fili gs with the Secu ities a d Excha ge Commissio .
Fo wa d-looki g stateme ts speak o ly as of the date of this p ess elease. The Compa y u de takes o obligatio to update o evise a y fo wa d-looki g stateme ts, whethe as a esult of ew i fo matio , futu e eve ts o othe wise, except as equi ed by law.
James Lambe t, Vice P eside tRube stei Public Relatio sPho e: 212.805.3024Email:
I vesto Relatio s:
###
